Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.60 |
| ▸ | NPC1 | O15118 | 7/20 | 0.60 |
| ▸ | HPGD | P15428 | 6/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL422787 | 0.98 | RAB9A (0.62) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL27945491 | 0.93 | RAB9A (0.57) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| Trifluoroacetic Acid SCHEMBL28285603 | 0.87 | HDAC3 (0.54) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL28472449 | 0.87 | RAB9A (0.49) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL9495199 | 0.84 | ALDH1A1 (0.61) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL27412610 | 0.83 | RAB9A (0.51) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL9147021 | 0.82 | RAB9A (0.48) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL27388065 | 0.82 | ALDH1A1 (0.60) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL11097691 | 0.81 | KMT2A (0.55) | RAB9ANPC1HPGDSMN1; SMN2TP53 | |
| SCHEMBL1433300 | 0.81 | NPC1 (0.60) | RAB9ANPC1HPGDSMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040266827-A1 | Convergent asymmetric route to produce a key intermediate towards the synthesis of a garft inhibitor | AGOURON PHARMACEUTICALS, INC. | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266827-A1 | Convergent asymmetric route to produce a key intermediate towards the synthesis of a garft inhibitor | SULT1A1, SULT1E1, SULT2A1 | RAB9A 3242/4885NPC1 2226/4885HPGD 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.